Patent intelligence · US
US 9566310
Methods of treating muscular dystrophy
Methods of treating muscular dystrophy
Patent details — US 9566310
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 14, 2017
- Expiration
- Feb 9, 2037
- Claims
- 12
- CPC classes
- A61K, A61K31/16, A61K31/19, A61K31/20
Quick answer
US 9566310 (Methods of treating muscular dystrophy) is held by BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE OF THE UNIVERSITY OF NEVADA, RENO. Status: granted. Granted Feb 14, 2017. Expires Feb 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/16, A61K31/19, A61K31/20, A61K31/277, A61K31/341
More from BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE OF THE UNIVERSITY OF NEVADA, RENO
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9566310?
US 9566310 (Methods of treating muscular dystrophy) is held by BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE OF THE UNIVERSITY OF NEVADA, RENO. Status: granted. Granted Feb 14, 2017. Expires Feb 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9566310?
BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE OF THE UNIVERSITY OF NEVADA, RENO is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9566310 expire?
Our index shows an expiration date of Feb 9, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.